|
시장보고서
상품코드
2075761
톡소플라즈마증 치료제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 유통 채널별 및 지역별Toxoplasmosis Treatment Drugs Market by Drug Class, by Indication, by Route of Administration, by Distribution Channel, and By Region |
||||||
톡소플라즈마증 치료제 시장은 2026년에 38억 7,200만 달러 규모로 추정되며, 2033년까지 56억 3,240만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 5.5%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 38억 7,200만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 5.50% | 시장 규모 예측(2033년) : | 56억 3,240만 달러 |
톡소플라즈마증은 톡소플라즈마 곤디이(Toxoplasma gondii)라는 기생충에 의해 발생하는 감염증입니다. 현재 권장되는 톡소플라즈마증 치료제는 기생충의 타키조이트기를 표적으로 하며, 조직에서 기생충을 제거하는 것은 아닙니다. 피리메타민은 가장 효과적인 항톡소플라즈마 약물로 여겨지며, 치료의 표준 구성 요소로 자리 잡고 있습니다. 피리메타민은 엽산 길항제로, 용량 의존적인 골수 억제를 유발할 가능성이 있으나, 이는 엽산(레보코린)을 병용 투여함으로써 완화됩니다. 로이코볼린은 피리메타민의 독성 작용으로부터 골수를 보호합니다. 환자가 설파제제에 과민 반응을 보일 경우, 설파디아진이나 클린다마이신 등 다른 약물을 추가로 투여해야 합니다. 또한, 톡소플라즈마증의 치료에는 트리메토프림과 설파메톡사졸의 고정용량 복합제나, 아토바콘, 피리메타민, 아지스로마이신 등의 다른 약물도 사용됩니다.
시장 역학
의약품은 활동성 감염증의 치료에 사용됩니다. 이러한 요인에는 질병의 중증도, 면역 체계의 상태, 감염 부위 등이 포함됩니다. 또 다른 측면은 임신 단계입니다. 예를 들어, 2022년 11월 3일, 미국에 본부를 둔 메이요 클리닉은 미생물에 의한 감염증과 싸우는 피리메타민(달라프림)에 대해 설명한 기사를 발표했습니다. 이 약제는 체내에서 엽산의 이용을 저해할 가능성이 있습니다. 장기 복용으로 인한 기타 부작용으로는 골수 억제 및 간독성 등이 있습니다. 칼슘-레보코린은 피리메타민이 엽산에 미치는 영향을 교정하는 데 도움이 됩니다. 설파디아진은 피리메타민과 병용하여 처방되는 경우가 많은 항생제입니다. 그 밖의 약물로는 클린다마이신(크레오신), 아지스로마이신(지스로맥스) 등이 있습니다. 신생아의 톡소플라즈마증을 진단하기 위해서는 감염이 의심될 경우 혈액 검사를 실시합니다. 검사 결과가 양성으로 나온 영아에게는 질환을 정확히 파악하고 경과를 관찰하기 위해 여러 가지 검사가 실시됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 세계 톡소플라즈마증 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 톡소플라즈마증 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 톡소플라즈마증 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 톡소플라즈마증 치료제 시장 : 약제 클래스별(2021-2033년)
제5장 세계의 톡소플라즈마증 치료제 시장 : 적응증별(2021-2033년)
제6장 세계의 톡소플라즈마증 치료제 시장 : 투여 경로별(2021-2033년)
제7장 세계의 톡소플라즈마증 치료제 시장 : 유통 채널별(2021-2033년)
제8장 세계의 톡소플라즈마증 치료제 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 섹션
AJY 26.07.09Toxoplasmosis Treatment Drugs Market is estimated to be valued at USD 3,872.0 Mn in 2026 and is expected to reach USD 5,632.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,872.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.50% | 2033 Value Projection: | USD 5,632.4 Mn |
Toxoplasmosis is an infection caused by a parasite called Toxoplasma gondii. Currently recommended toxoplasmosis drugs target the tachyzoite stage of the parasite and do not remove the parasite from the tissues. Pyrimethamine is considered the most effective anti-toxoplasmosis drug, and it is a standard component of treatment. Pyrimethamine is a folic acid antagonist and can cause dose-dependent bone marrow suppression, which is alleviated by the concomitant administration of folic acid (leucovorin). Leucovorin protects the bone marrow from the toxic effects of pyrimethamine. If the patient experiences a hypersensitive reaction to sulfa medications, another medication, such as sulfadiazine or clindamycin, should be added. As an alternative, a fixed combination of trimethoprim with sulfamethoxazole and other drugs such as atovaquone and pyrimethamine and azithromycin are used for toxoplasmosis treatment.
Market Dynamics
Medicines are used to treat active infections. These factors include the severity of your illness, the state of your immune system, and the location of the infection. Another aspect is pregnancy's stage. For example, on November 3, 2022, a U.S.-based hospital, Mayo Clinics published an article explaining pyrimethamine (Daraprim), which fights against infections caused by microscopic organisms. It can block the body's use of folic acid. Other possible side effects of its long-term use include bone marrow suppression and liver toxicity. Leucovorin calcium helps correct the effect of pyrimethamine on folic acid. Sulfadiazine is an antibiotic often prescribed with pyrimethamine. Other medications include clindamycin (Cleocin), azithromycin (Zithromax), and others. To diagnose toxoplasmosis in a newborn baby, blood tests are prescribed if infection is suspected. A baby with a positive test result will undergo many tests to identify and monitor the disease.
Key features of the study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global toxoplasmosis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F.Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market
Detailed Segmentation:
- Global Toxoplasmosis Treatment Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Pyrimethamine
- Spiramycin
- Leucovorin
- Sulfadiazine
- Folic Acid
- Others
- Global Toxoplasmosis Treatment Drugs Market, By Indication (Revenue, USD Mn, 2021 - 2033)
- Chronic Toxoplasmosis Infection
- Acute Toxoplasmosis Infection
- Global Toxoplasmosis Treatment Drugs Market, By Route of administration (Revenue, USD Mn, 2021 - 2033)
- Parenteral
- Oral
- Global Toxoplasmosis Treatment Drugs Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Global Toxoplasmosis Treatment Drugs Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Company Profiles
- Vyera Pharmaceuticals LLC
- Taj Accura Pharmaceuticals Ltd
- Mangalam Drugs and Organics Ltd
- Cerovene Healthcare PVT LTD
- Greenstone LLC
- Amneal Pharmaceuticals, Inc.
- Turing Pharmaceuticals
- F.Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd
- Baxter International Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Toxoplasmosis Treatment Drugs Market, by Drug Class, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Pyrimethamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Spiramycin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Leucovorin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Sulfadiazine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Folic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
5. Global Toxoplasmosis Treatment Drugs Market, By Indication, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Chronic Toxoplasmosis Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Acute Toxoplasmosis Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
6. Global Toxoplasmosis Treatment Drugs Market, by Route of Administration, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
7. Global Toxoplasmosis Treatment Drugs Market, by Distribution Channel, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
8. Global Toxoplasmosis Treatment Drugs Market, By Region, 2021 - 2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Vyera Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taj Accura Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mangalam Drugs and Organics Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cerovene Healthcare PVT LTD
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Greenstone LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Turing Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F.Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Baxter International Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
